

Dear members of the ELN,

with the current newsletter we want to inform you about the latest input regarding the website-content.

■ **9th Annual Symposium of the ELN - Agendas**

Agendas for the upcoming 9th Annual Symposium of the European LeukemiaNet, January 31 to February 1, 2012, in Mannheim are now available online (http://www.leukemia-net.org/content/home/el_n_symposia/agendas/#e9560).

■ **AML post-remission treatment score**

The new AML post remission treatment score (PRT) allows for the online calculation of the predictive PRT score group for patients 15 to 60 years in complete remission after induction therapy. Please find this useful application on http://www.leukemia-net.org/content/leukemias/aml/aml_prt_score/.

■ **EUTOS score for CML**

Using spleen size and percentage of basophils the EUTOS score predicts the risk of not achieving a complete cytogenetic remission 18 months after the start of therapy in patients suffering from CML. The calculations can be performed online at http://www.leukemia-net.org/content/leukemias/cml/eutos_score/.

■ **Update of patient organizations**

The ELN intends to upgrade the multilingual website content and to provide national contacts for patients. So far, 17 European patient organizations are listed at http://www.leukemia-net.org/content/patients/patient_organizations/. If you have suggestions for other organizations to be included in this list, please contact ELIC@em.uni-frankfurt.de.

■ **Perspectives in Cell and Gene based Medicines (CGM)**

The CGM is a joint conference of the 18th Annual Meeting of the German Society for Gene Therapy, the Perspective Conference of the Foundation of Haemotherapy-Research on the role of Haemotherapy and Transfusion Medicine and the 1st Symposium of the LOEWE Center for Cell and Gene Therapy Frankfurt. Topics include regenerative medicine, clinical gene therapy, gene repair, immunotherapy, translational transfusion medicine, haemotherapy and haemophilia, reprogramming, iPS cells, human ES cells, miRNA, regulatory aspects, virotherapy, as well as cancer gene therapy. The meeting takes place at the Campus Westend of the Johann Wolfgang Goethe-University on March 15-17, 2012. For detailed information please go to http://www.leukemia-net.org/content/home/calendar/index_html?record_id=e9537.

■ **European Focus on Myeloproliferative Neoplasms & Myelodysplastic Syndromes**

The upcoming European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Congress is the first European-focused meeting on MPN und MDS. The meeting will be held in Lisbona, Portugal, on May 4-5, 2012. Topics are emerging research findings in new pathways for therapeutic

intervention, individualized management strategies, trends in transplantation, symptoms management, and emerging treatment options. For further information please visit http://www.leukemia-net.org/content/home/calendar/index_html?record_id=e9390.

■ 8th Information Letter

The current 8th Information Letter is now available at http://www.leukemia-net.org/content/home/information_letter/info_letter/. In this issue topics range from basic research to new clinical trials. As usual, it also gives an overview of the highlights from different work packages.

■ The ELN website is in compliance with the HONcode

The HONcode certificate confirms that the ELN website coincides with the 8 principles of the HONcode of Conduct. The HONcode certification is a quality criterion to show the transparency of the website and its intent of objectivity of the presented information.

Please have a look at <http://www.leukemia-net.org/content/home/> and <https://www.hon.ch/HONcode/Conduct.html?HONConduct611983>.

We hope you find this newsletter helpful.

Kind regards,
ELIC

Dr. Nicola Gökbüget
Dr. Sina Hehn
Kristina Ihrig

■ ■ European Leukemia Information Center - ELIC

Johann Wolfgang Goethe University Hospital
Department of Medicine II
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Germany

phone ++49 (0)69 6301 6365

mail ELIC@em.uni-frankfurt.de

web www.leukemia-net.org